Claim your virtual pass to watch online
No images? Click here
Tomorrow: Endpoints at #JPM26
JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
VIRTUAL + SAN FRANCISCO
Endpoints News will be live at JPM in San Francisco starting tomorrow — and you can get a front-row seat online. Join us virtually (it’s free!) as we kick off the day at 8 AM PT with:
- Reclaiming lost ground — with Mike Doustdar, CEO, Novo Nordisk
- The dealmaking forecast for 2026 — Moderated by John Carroll
- The IPO: Re-opening the markets with Heather Turner, CEO of LB Pharmaceuticals Inc
- 2026: The new priorities in oncology R&D and diagnostics — Moderated by John Carroll
- Conversations on rare disease outlook at the FDA, manufacturing during global policy uncertainty, and the M&A landscape with Eric Tokat, Co-President of Centerview Partners
Access to the livestream is available at no charge on both January 12 and 13. Choose a virtual pass to join us live.
Free virtual programming will run from 8 AM - 12 PM PT each day.
The story behind the deals happening right now
John Carroll sits down with dealmakers from Amgen, PwC, and AbbVie to discuss the M&A surge that delivered multiple $10 billion acquisitions despite the broader downturn. They'll examine whether this momentum continues into 2026 or if buyers pull back. Which biotechs will survive, and which will become the next targets?
In-person passes include access to our invite-only networking reception, featuring a live taping of Post-Hoc Live and special guest Noubar Afeyan, Founder and CEO of Flagship Pioneering.
CHOOSE YOUR PASS
Virtual passes are available at no charge
Join us in-person on Monday & Tuesday
Join us in-person on Monday or Tuesday
Join us virtually (free)
FEATURED SESSION
The executives steering biopharma through its toughest period are ready to share what they're seeing. Mike Doustdar, CEO of Novo Nordisk, took the helm as the obesity market Novo pioneered became increasingly competitive. After several months leading the Danish giant, he's sitting down with Drew Armstrong to discuss his vision for reclaiming Novo's edge.
Mike Doustdar
CEO, Novo Nordisk
Virtual passes are available at no charge
Join us virtually for free
EVENT SPONSORS
